AstraZeneca recently announced its Zurampic licensing agreement with Grünenthal GmbH.
Zurampic (lesinurad) is a selective uric acid reabsorption
inhibitor (SURI) that is used in conjunction with xanthine oxidase inhibiters (XOIs)
to treat uncontrolled gout.
“We are highly committed to the research, development and commercialization of innovative therapies that bring true benefits to patients," Grünenthal CEO Dr. Eric-Paul Pâques said. "Zurampic is a strong addition to our existing portfolio of innovative therapies in the areas of inflammatory diseases and chronic pain. We will thus use our capabilities to provide patients in our markets with this innovative new medicine to better control their condition.”
The licensing agreement provides that Grünenthal will proceed with the regulatory reviews. AstraZeneca will receive up to $230 million in sales plus royalties on annual product sales. Grünenthal has the option to take over manufacturing of the medication in October 2021. Until then, AstraZeneca will continue to manufacture Zurampic for Grünenthal.
“Grünenthal has an established presence across European and Latin American markets and extensive expertise in inflammatory diseases," AstraZeneca's Global Product and Portfolio Strategy EVP Luke Miels said. "This agreement allows us to further focus our resources on our strategic priorities.”
Alerts Sign-up